- Trials with a EudraCT protocol (23)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
23 result(s) found for: Pulmonologist.
Displaying page 1 of 2.
EudraCT Number: 2006-006469-17 | Sponsor Protocol Number: 2006-001 | Start Date*: Information not available in EudraCT |
Sponsor Name:St Olavs Hospital, University Hospital of Trondheim [...] | ||
Full Title: A multicenter study to investigate the Sensitivity and Specificity of Aridol (Mannitol)Challenge as compared with Methacholine Challenge to predict a diagnosis of Asthma by a Specialist Pulmonologi... | ||
Medical condition: The detection of bronchial hyperresponsiveness in patients with suspected asthma | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001317-28 | Sponsor Protocol Number: ABBA-2 | Start Date*: 2015-07-30 |
Sponsor Name:UMC Utrecht | ||
Full Title: A B2-agonist as a CFTR activator in CF - Part 2 | ||
Medical condition: Cystic fibrosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001570-42 | Sponsor Protocol Number: AirGOs-2 | Start Date*: 2018-05-07 |
Sponsor Name:Helsinki University Hospital | ||
Full Title: Aggravated airway inflammation: research on genomics and optimal treatments (AirGOs) | ||
Medical condition: Acetylsalicylic acid (ASA-) exacerbated respiratory disease (AERD). | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FI (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003025-37 | Sponsor Protocol Number: 2020AFA01 | Start Date*: 2020-10-06 |
Sponsor Name:VU University Medical Center | ||
Full Title: COMBINING AFATINIB AND CONCURRENT CHEMOTHERAPY, FOLLOWED BY OSIMERTINIB AND CONCURRENT CHEMOTHERAPY, IN UNTREATED EGFR POSITIVE NSCLC TUMORS | ||
Medical condition: non small cell lung cancer (NSCLC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002165-34 | Sponsor Protocol Number: RC19_0292 | Start Date*: 2020-12-03 | |||||||||||
Sponsor Name:CHU of Nantes | |||||||||||||
Full Title: Predictive Signature of Benralizumab Response | |||||||||||||
Medical condition: Severe asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005648-93 | Sponsor Protocol Number: CD-IA-CAM-3001-1109 | Start Date*: 2012-07-19 | |||||||||||
Sponsor Name:MedImmune Ltd | |||||||||||||
Full Title: An Open-label Extension Study to Evaluate the Long-term Safety of Mavrilimumab in Adult Subjects with Rheumatoid Arthritis | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) HU (Completed) CZ (Completed) DE (Completed) ES (Completed) BG (Completed) GR (Completed) SK (Completed) PT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003799-22 | Sponsor Protocol Number: CVT-301-005 | Start Date*: 2015-02-11 | |||||||||||
Sponsor Name:Civitas Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Obser... | |||||||||||||
Medical condition: Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) GB (Completed) CZ (Completed) DE (Completed) ES (Completed) BE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001996-39 | Sponsor Protocol Number: A2171069 | Start Date*: 2006-07-13 | |||||||||||
Sponsor Name:Pfizer Pharma GmbH | |||||||||||||
Full Title: AN INTERNATIONAL, MULTICENTER, LARGE SIMPLE TRIAL (LST) TO EVALUATE THE LONG-TERM PULMONARY AND CARDIOVASCULAR SAFETY OF EXUBERA® IN PATIENTS WITH DIABETES MELLITUS | |||||||||||||
Medical condition: Diabetes Mellitus Type I and Type II | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005626-19 | Sponsor Protocol Number: CVT-301-004E | Start Date*: 2016-06-23 | |||||||||||
Sponsor Name:Civitas Therapeutics, Inc. | |||||||||||||
Full Title: A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) | |||||||||||||
Medical condition: Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005067-17 | Sponsor Protocol Number: CVT-301-004 | Start Date*: 2016-04-01 | |||||||||||
Sponsor Name:Civitas Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response Fluct... | |||||||||||||
Medical condition: Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003900-28 | Sponsor Protocol Number: TOFA-PREDICT | Start Date*: 2018-04-04 |
Sponsor Name:UMC Utrecht | ||
Full Title: A Stratification trial to determine key immunological factors predicting Tofacitinib efficacy in Psoriatic Arthritis (PsA). TOFA-PREDICT | ||
Medical condition: psoriatic arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003453-34 | Sponsor Protocol Number: 201755 | Start Date*: 2015-06-18 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A Phase IIb, Double-Blind, Placebo-Controlled, Dose-Adaptive, Study of the Efficacy and Safety of GSK3196165 in Combination with Methotrexate Therapy, in Subjects with Active Moderate-Severe Rheuma... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) DE (Completed) HU (Completed) CZ (Completed) ES (Completed) GB (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000808-41 | Sponsor Protocol Number: 1237.11 | Start Date*: 2013-08-27 | |||||||||||
Sponsor Name:Boehringer Ingelheim España, S.A. | |||||||||||||
Full Title: Randomized, double-blind, double-dummy, active-controlled, 4 period complete cross-over study to compare the effect on lung function of 6 weeks once daily treatment with orally inhaled tiotropium+o... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) NL (Completed) CZ (Completed) BE (Completed) DK (Completed) SE (Completed) HU (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002169-39 | Sponsor Protocol Number: A3921092 | Start Date*: 2014-03-26 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS Paediatric investigation plan numbers - (P/144/2010),(P/162/2011) and (P/0064/2012). | |||||||||||||
Medical condition: Psoriatic arthritis (PsA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) CZ (Completed) BG (Completed) SK (Completed) PL (Completed) ES (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006299-39 | Sponsor Protocol Number: 191622-082-01 | Start Date*: 2008-04-23 | |||||||||||
Sponsor Name:Allergan | |||||||||||||
Full Title: A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Neurogenic Detrusor Overactivity and Neurological Respira... | |||||||||||||
Medical condition: Patients with urinary incontinence due to neurogenic detrusor overactivity as a result of spinal cord injury or multiple sclerosis who have not been adequately managed with anticholinergic therapy ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002004-39 | Sponsor Protocol Number: BAT-2506-002-CR | Start Date*: 2021-04-23 | |||||||||||
Sponsor Name:Bio-Thera Solutions, Ltd. | |||||||||||||
Full Title: A Multicenter, Double-blind, Randomized, Parallel-group Study to Compare the Efficacy and Safety of BAT2506 Versus Simponi® in Participants with Active Psoriatic Arthritis | |||||||||||||
Medical condition: Psoriatic arthritis (PsA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022458-18 | Sponsor Protocol Number: 205.425 | Start Date*: 2011-05-23 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A phase II randomised, double-blind, placebo-controlled incomplete cross-over trial with 4-week treatment periods to evaluate efficacy and safety of tiotropium inhalation solution (doses of 1.25 μg... | |||||||||||||
Medical condition: Moderate persistent asthma in children 6 to 11 years old | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) LV (Completed) LT (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017745-55 | Sponsor Protocol Number: 205.424 | Start Date*: 2010-05-03 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A Phase II randomised, double-blind, placebo-controlled, incomplete crossover trial with 4-week treatment periods to evaluate efficacy and safety of tiotropium inhalation solution (doses of 1.25μg,... | |||||||||||||
Medical condition: Moderate persistent asthma in adolescents (12 to 17 years old) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SI (Completed) LT (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001254-22 | Sponsor Protocol Number: SARPAC | Start Date*: 2020-03-24 | |||||||||||
Sponsor Name:University Hospital Ghent | |||||||||||||
Full Title: A prospective, randomized, open-label, interventional study to investigate the efficacy of sargramostim (Leukine®) in improving oxygenation and short- and long-term outcome of COVID-19 patients wit... | |||||||||||||
Medical condition: Acute hypoxic respiratory failure of COVID-19 patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001413-14 | Sponsor Protocol Number: 205.416 | Start Date*: 2008-08-20 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat ® inhaler (5 μg/day) over 48 ... | |||||||||||||
Medical condition: Patients with severe persistent asthma who are still symptomatic despite being treated with high-dose inhaled corticosteroids and long-acting beta2-agonists. Additional asthma treatments are allowe... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
